IL17A and asthma: In this context, it is predictable that a therapeutic strategy targeting a single mediator of non-type 2 immune response such as IL-17A (brodalumab, a human anti-IL-17RA monoclonal antibody) does not produce a remarkable treatment effect in subjects with moderate to severe asthma in clinical studies [49].